Annual report
4521.TEDINET S100R4OM
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥73.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥76.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥75.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥89.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥94.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥8.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥17.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.9bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥25.0bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥6.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥13.9bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥19.4bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥17.8bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥9.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥166.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥165.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥163.3bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥157.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥156.0bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥29.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥26.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥136.8bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥138.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥136.3bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥128.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥121.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥59.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥61.0bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥74.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥74.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥77.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥73.3bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥58.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥9.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥13.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥14.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥27.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥21.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥7.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥7.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥10.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥144.8 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥251.43 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥347.37 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥494.89 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥445.78 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,636.17 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,642.34 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,555.93 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,301.09 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,049.78 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 81.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 81.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.5% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,130 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,164 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 1,215 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 1,268 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,341 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥72.9bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥75.9bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥73.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥87.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥92.5bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥8.4bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥17.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.9bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.9bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥24.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥14.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥9.9bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥13.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥19.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥17.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥163.7bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥161.8bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥162.3bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥156.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥154.3bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥27.2bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥25.2bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥136.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥136.6bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥135.0bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥128.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥120.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥58.3bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥59.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥180.07 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥260.61 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥346.63 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥493.31 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥443.8 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥150 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥150 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,644.33 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,611.75 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,521.92 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,306.96 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,045.17 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.1% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.5% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 45,939,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 45,939,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,439,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,117 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 1,152 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 1,207 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 1,258 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 1,333 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥82.0bn |
| Medicinereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Medicinereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| Medicinereportable segment | employees | at 2023-03-31 | 1129 pure |
| Medicinereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥70.6bn |
| Medicinereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥70.6bn |
| Medicinereportable segment | segment assets | at 2023-03-31 | ¥74.2bn |
| Medicinereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥6.7bn |
| Real Estatereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥19m |
| Real Estatereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥322m |
| Real Estatereportable segment | employees | at 2023-03-31 | 1 pure |
| Real Estatereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Real Estatereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Real Estatereportable segment | segment assets | at 2023-03-31 | ¥10.1bn |
| Real Estatereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.3bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥73.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥73.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥84.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥8.0bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥79.2bn |
| Medicinereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥11.3bn |
| Medicinereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Medicinereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥73.6bn |
| Medicinereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥73.6bn |
| Medicinereportable segment | segment assets | at 2022-03-31 | ¥75.6bn |
| Medicinereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥15.7bn |
| Real Estatereportable segment | capex | 2021-04-01 → 2022-03-31 | ¥508m |
| Real Estatereportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥322m |
| Real Estatereportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥2.4bn |
| Real Estatereportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥2.4bn |
| Real Estatereportable segment | segment assets | at 2022-03-31 | ¥10.4bn |
| Real Estatereportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥11.9bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥76.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥86.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥17.1bn |
| Medicinereportable segment | employees | at 2023-03-31 | 1116 pure |
| Real Estatereportable segment | employees | at 2023-03-31 | 1 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,718
| Item | Context | Value | Unit |
|---|---|---|---|
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)㈱スズケン | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row19Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)㈱ニッピ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)原材料仕入に係る取引円滑化や協業関係への発展のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row20Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)クミアイ化学工業㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)農業薬品原体販売及び製造や農薬の取り扱いにおいて協力関係を維持・発展するために保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row21Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Original text (Japanese)㈱ほくやく・竹山ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Original text (Japanese)医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row22Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Original text (Japanese)㈱バイタルケーエスケー・ホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Original text (Japanese)医薬品販売に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row23Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | Original text (Japanese)㈱三菱ＵＦＪフィナンシャル・グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | Original text (Japanese)金融機関として取引の円滑化、金融関連情報の継続的な提供を受けるために保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row24Member | Original text (Japanese)有 | |
| Name of securities details of deemed holdings of equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)東レ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)退職給付信託契約に基づく議決権行使の指図権 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of deemed holdings of shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes additional information consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding amounts of notes and accounts receivable trade and contract assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of contract liabilities (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of revenue from contracts with customers (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding write downs of inventories (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding gain on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on sales of property plant and equipment (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding loss on disposal of property plant and equipment (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |